From: The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
Classification | Frequency(%) |
---|---|
Status | |
Proceeding | 851 (34.5%) |
Completed | 1529 (62.0%) |
Suspended | 20 (0.8%) |
Terminated | 66 (2.7%) |
Trials Phase | |
Phase IV | 26 (1.1%) |
Phase III | 278 (11.3%) |
Phase II | 169 (6.9%) |
Phase I | 555 (22.5%) |
Bioequivalence | 1438 (58.3%) |
Type of drugs | |
Chemical Drug | 2079 (84.3%) |
Biological Product | 209 (8.5%) |
TCM Compound | 97 (3.9%) |
Ingredient of Natural Drug | 60 (2.4%) |
NA | 21 (0.9%) |
Design | |
Single-arm | 100 (4.1%) |
Crossover | 1663 (67.4%) |
Parallel-group | 698 (28.3%) |
Factorial design | 5 (0.2%) |
Randomization | |
Randomization | 2353 (95.4%) |
Non-randomization | 113 (4.6%) |
Blinding | |
Open-label | 1867 (75.7%) |
Single-blind | 35 (1.4%) |
Double-blind | 564 (22.9%) |
Coverage | |
Domestic | 2401 (97.4%) |
International Multi-center | 65 (2.6%) |